期刊文献+

脂质体-c-raf-1反义寡核苷酸治疗人卵巢癌裸鼠皮下移植瘤

Effect of liposome-c-raf-1 antisense oligodeoxynucleotides on human ovarian carcinoma transplanted subcutaneously in nude mice
下载PDF
导出
摘要 目的 :探讨c-raf- 1反义寡脱氧核苷酸 (ASODN)对人卵巢癌裸鼠皮下移植瘤的治疗作用。方法 :将 15只裸鼠建立人卵巢癌裸鼠皮下移植瘤模型 ,然后随机分成 3组予以不同条件处理 :对照组 (腹腔注射转染液和脂质体 ) ,正义治疗组 (腹腔注射脂质体 -c -raf- 1-SODN) ,反义治疗组 (腹腔注射脂质体 -c -raf- 1-ASODN)。治疗期间定期观测裸鼠体重并测量肿瘤体积 ,计算抑瘤率及肿瘤缩小率。结果 :反义治疗组与正义治疗组的抑瘤率分别为 6 8.1%和 6 .8% ,反义治疗组肿瘤缩小率为 16 .7% ,与正义治疗组相比较有明显的差别。各组裸鼠体重变化无明显差别。结论 :脂质体 -c -raf - 1-ASODN对人卵巢癌裸鼠皮下移植瘤有一定的治疗价值 。 Objective:To explore the effect of c-raf-1 antisense oligodeoxynucleotides (ASODN) treatment in the human ovarian epithelial cancer transplanted subcutaneously in nude mice.Methods:The models of human ovarian epithelial cancer transplanted subcutaneously were established in 15 nude mice,then divided randomly into 3 groups and different treatment were given respectively (control group,senseexperimental group and antisense experimental group).The weight of nude mice and tumor volume were observed,the tumor growth inhibitory rate and the tumor response rate calculated,too.Results:The growth inhibitory rate in sense experimental group and antisense experimental group were 6.8% and 68.1%,respectively,the tumor response rate of antisense experimental group was 16.7%.There was no statistical difference in nude mice weight among the 3 groups.Conclusion:The results suggest that there is a positive value in the human ovarian epithelial cancer transplanted subcutaneously in nude mice treated by c-raf-1 antisense oligodeoxynucleotides,which will be an important gene therapeutic strategy for the ovarian epithelial carcinoma in the future.
出处 《重庆医科大学学报》 CAS CSCD 2004年第3期302-304,共3页 Journal of Chongqing Medical University
关键词 反义寡脱氧核苷酸 c-raf-1基因 人卵巢上皮癌 裸鼠皮下移植瘤 Antisense oligodeoxynucleotides c-raf-1gene Ovarian epithelial carcinoma Tumor transplanted subcutaneously in nude mice
  • 相关文献

参考文献11

  • 1沈梅,丰有吉,周先荣,姚明.脂质体-C-erbB_2反义寡核苷酸对人卵巢上皮癌裸鼠皮下移植瘤的作用[J].现代妇产科进展,1998,7(4):314-316. 被引量:6
  • 2O'Dwyer PJ ,Stevenson JP,Gallagher M,et al.C-raf-1 depletion and Tumor Responses in Patients Treated with the C -raf-1 Antisense oligodeoxynucleotide IsIs5132 (CGP 68936A) [J ].Clin Cancer Res,1999 ; 5(12):3977-3982.
  • 3Wadler S.New developments in treatment of ovarian cancer[J ].Expert Opin Investig Drugs,2001; 10(6):1167-1172.
  • 4Marcusson EG,yacyshyn BR,shanahan W J,et al.Preclinical and clinical pharmacolgy of antisense oligonucleotides [J ].Mol Biotechnol,1999; 12(1):1-11.
  • 5Kim CK,Haider KH,Choi CU.Nonviral vector for efficient gene transfer to human ovarian adenocarcinoma cells.Gyneol Oncol,2002; 84(1) :85-93.
  • 6Harries M,Kaye SB.Recent advances in the treatment of epithelial ovarian eancer[J ].Expert Opin Investig Drugs,2001;10(9):1715-1724.
  • 7Ozols,Robert F.Future directions in the treatment of ovarian cancer[ J ].Semin Oncol,2002; 29(1 supp1):32-42.
  • 8Guha C,Guha U,Tribius S,et al.Antisense ATM gene therapy:a strategy to increase the radiosensitivity of human tumors[ J ].Gene Ther,2000; 7 (10):852-858.
  • 9Pietras K,Ostman A,Sjioquist M,et al.Inhibition of platelet-derived Growth Factor Receptor reduces interstitial hypertension and increase transcapillary transport in tumor[J].Cancer Res,2001 ;61:2929-2934.
  • 10King Bl,Carter D,Foellmer HG,et al.Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines[J ].Am J pathol,1992;140:23-31.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部